Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Technology that could double the effectiveness of cancer drugs studied at Yale

24.01.2005


To identify the best treatment for recurrent ovarian cancer, researchers at Yale School of Medicine are studying a technology called the Yale apoptosis assay in combination with another technology called the ChemoFX assay, which could double the response rate to existing drugs.



In patients with recurrent ovarian cancer, it is often difficult to select an effective treatment because the tumor develops resistance to many drugs. Currently, physicians select a drug and must wait about six months to see whether it is effective on a particular patient.

"These two new assays will take the guesswork out of cancer treatment," said lead investigator, Gil Mor, M.D., associate professor of obstetrics and gynecology and reproductive sciences at Yale School of Medicine. "In patients with very limited time left to live, six months can feel like an eternity when they may have to start a whole new course of treatment if it proves ineffective."


Mor’s lab developed the Yale apoptosis assay based on a biological principle that when a drug is effective, it will induce apoptosis (cell death) in the cancer cell. If the cancer cell is resistant to a drug, apoptosis does not occur.

Mor said, "The Yale apoptosis assay will determine whether a drug kills the tumor. The ChemoFX assay will determine whether a drug stops tumor growth. Used together, both assays will distinguish drugs that can stop the growth of the tumor and/or kill the tumor. This was not possible before." "This test will help physicians predict whether a patient will respond to a specific drug, much like they test bacteria for sensitivity to antibiotics," Mor added.

The technology will be studied with various cancers, beginning with ovarian cancer. The clinical trial is a multi-center study for validation of the assays. Each assay will be evaluated independently and then in combination. The Yale research team partnered with Precision Therapeutics, Inc., (PTI) developers of the ChemoFX assay and is seeking patients from Yale and surrounding communities and from 10 other sites around the country. PTI exclusively licensed the Yale apoptosis assay from Yale. Recruitment for the study will be complete in June 2005, with results available about one year later. The Yale clinical trial is led by Thomas Rutherford, M.D., associate professor of gynecology at Yale School of Medicine.

Karen N. Peart | EurekAlert!
Further information:
http://www.yale.edu

More articles from Health and Medicine:

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

nachricht Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

Im Focus: Quantum-physical Model System

Computer-assisted methods aid Heidelberg physicists in reproducing experiment with ultracold atoms

Two researchers at Heidelberg University have developed a model system that enables a better understanding of the processes in a quantum-physical experiment...

Im Focus: Glacier bacteria’s contribution to carbon cycling

Glaciers might seem rather inhospitable environments. However, they are home to a diverse and vibrant microbial community. It’s becoming increasingly clear that they play a bigger role in the carbon cycle than previously thought.

A new study, now published in the journal Nature Geoscience, shows how microbial communities in melting glaciers contribute to the Earth’s carbon cycle, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

New quantum liquid crystals may play role in future of computers

21.04.2017 | Physics and Astronomy

A promising target for kidney fibrosis

21.04.2017 | Health and Medicine

Light rays from a supernova bent by the curvature of space-time around a galaxy

21.04.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>